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Conventionally fractionated radiotherapy (RT) has 
been a stalwart radiation-based treatment modality 
for intracranial meningioma for decades, providing 
excellent tumor control (1). Although the majority of 
patients receive conventional photon-based therapy, the 
physical properties of proton beam make this radiation 
modality very attractive, leading to a dramatic growth 
in the number of proton centers across the United 
States (2). The increasing popularity of protons over 
the past decade may lead to increased proton utilization 
in the management of benign conditions, where long-
term survival is expected, such as meningioma (3). A 
recent randomized study of RT from the Massachu-
setts General Hospital involving an 80%/20% proton/
photon ratio during treatment for subtotally resected/
recurrent benign meningioma patients found the risk 
of stroke was 20.5%, with the average stroke develop-
ing 5.6 years after RT completion (4). This high rate is 
worrisome and puts the safety of external beam radia-
tion therapy in the management of benign meningioma 
under question. However, before rejecting radiation 
therapy as a management for benign meningiomas, 
it is important to determine whether this high rate of 
stroke is also evident in patients treated with photon-
based conventionally fractionated RT. This study was 
performed to address this void.
Studies examining RT for meningioma were 
assessed using an extensive search of the PubMed data-
base. Search terms used were “long-term”, “fraction-
ated”, “radiotherapy”, and “meningioma”. To optimize 
stroke inclusion, only studies with mean/median clini-
cal follow-up of at least six years were included in the 
final analysis in order to exceed the 5.6 year lag time 
between completion of RT and stroke development 
established by Sanford et al. (4). Additional inclusion 
criteria were: a) minimum of 30 patients, b) English 
language, c) exclusive RT patient population, d) exclu-
sive meningioma population, e) comprehensive post-
RT morbidity analysis, and f) non-duplicant patient 
pool. Proton therapies were excluded from the analysis. 
The stroke rate for each article was assessed either from 
being directly described in the manuscript, or from 
extrapolating post-RT complications from reported 
clinical examinations (i.e. hemiparesis/weakness, pitui-
tary dysfunction following treatment of cavernous sinus 
lesions given the known course of the internal carotid 
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artery in that anatomic region) at last follow-up in order 
to rule out transient events. Results were then culled 
to determine an overall stroke rate. Six studies exam-
ining RT for meningioma with long-term follow-up 
met inclusion criteria, providing a total of 303 patients 
as shown in Table 1 (5-10). Median/mean follow-up 
ranged from 78 to 168 months. Operative meningi-
oma resection prior to fractionated RT occurred in 213 
patients (70.3%). Mean total dose ranged from 45.1 
Gy to 57.6 Gy; the mean dose per fraction ranged from 
1.7 to 2.0 Gy (Table 1). Seventeen patients suffered a 
stroke following RT, for a stroke rate of 5.6% (Table 1); 
the vast majority of these strokes were deduced from 
reported clinical manifestations, most predominantly 
hemiparesis either caused or worsened by RT. All six 
studies used exclusively photons for RT. 
The results of our PubMed database search show a 
dramatically lower long-term stroke rate at 5.6% with 
photon-based therapy. This rate is in line with the normal 
expected rate of stroke for people ages 40-79 according 
to the American Heart Association (11). Therefore, it is 
possible that the high stroke rate seen in the randomized 
clinical trial may be related to the use of proton beam; 
another possibility, independent of technique, is the 
dose prescription in both arms of that study. Addition-
ally, the Bragg peak phenomenon may have resulted in 
a higher radiobiological effect upon adjacent cerebral 
vessels thereby resulting in vascular damage. The retro-
spective nature of this study and inability to determine 
the individual dosing, follow-up, treatment plans, and 
detailed clinical course (symptom onset, intervention, 
imaging findings, etc.) of the 17 patients who suffered 
post-photon RT stroke are limitations of this study. 
Another limitation is that the deductive approach used 
for identifying stroke could potentially overestimate 
or underestimate the true incidence of stroke follow-
ing RT. Nevertheless, this information suggests that 
additional studies are greatly needed to determine the 
most effective and safe method of treating patients with 
benign meningiomas.
In conclusion, the long-term stroke risk of RT using 
photons is 5.6%, in line with the expected rate of stroke 
development in a general population. Given that the 
results of Sanford et al. are based on an 80% proton-
based therapy, it is pertinent to wonder whether the 
long-term stroke morbidity of 100% proton-based RT 
may be higher than their 20.5% rate. Further studies 
with sufficient follow-up will be required to definitively 
address this issue.
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Table 1. Studies meeting inclusion criteria (minimum clinical follow-up = 72 months) for long-term stroke evaluation 
following fractionated radiotherapy (RT) for meningioma
Reference
No. 
patients
Follow-up 
(months)
Resection 
prior to 
RT
RT as 
primary 
treatment
Clinical 
evidence 
of stroke
Stroke 
incidence
(%)
Mean dose 
(Gy)
Mean dose 
per fraction 
(Gy)
RT 
modality
5 61a 108 
(median)
61 0 7 11.5 57.5 1.7 Photon
6 49 168 
(median)
34 15 3 6.1 45.1 2.0 Photon
7 45 108 
(mean)
45 0 7 15.6 52.0 1.8 Photon
8 38 89 
(median)
20 18 0 0 53.0 1.9 Photon
9 57 78 
(median)
28 29 0 0 57.6 1.8 Photon
10 53 83 
(median)
25 28 0 0 52.9 1.9 Photon
Total 303 213 90 17 5.6
aAssessable for late toxicity (of the 82 patients total in this study).
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